Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 17/20 | 0.54 |
| ▸ | CYBB | P04839 | 12/20 | 0.54 |
| ▸ | NOX5 | Q96PH1 | 11/20 | 0.49 |
| ▸ | NOX1 | Q9Y5S8 | 11/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523655 | 1.00 | NOX4 (0.54) | NOX4CYBBNOX5NOX1MAPT | |
| SCHEMBL14931627 | 0.92 | NOX4 (0.53) | NOX4CYBBNOX5NOX1MAPT | |
| SCHEMBL29523201 | 0.92 | NOX4 (0.53) | NOX4CYBBNOX5NOX1MAPT | |
| SCHEMBL29523126 | 0.88 | NOX4 (0.51) | NOX4CYBBNOX5NOX1GABRA1 | |
| SCHEMBL14931684 | 0.88 | NOX4 (0.51) | NOX4CYBBNOX5NOX1GABRA1 | |
| SCHEMBL29523256 | 0.88 | NOX4 (0.51) | NOX4CYBBNOX5NOX1MAPT | |
| SCHEMBL14931691 | 0.88 | NOX4 (0.51) | NOX4CYBBNOX5NOX1MAPT | |
| SCHEMBL29523172 | 0.87 | NOX4 (0.72) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL14931562 | 0.87 | NOX4 (0.72) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL14931723 | 0.83 | NOX4 (0.51) | NOX4CYBBNOX5NOX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | claimed |
| CN-111971284-A | COMBINATION MODES OF NUCLEOSIDE AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELLIS-SPECIFIC ANTIVIRAL AGENTS | 埃默里大学 | 2020-11-20 | — | — | CN | claimed |
| EP-3732180-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | Emory University (US) | 2020-11-04 | — | — | EP | claimed |
| EP-2776027-B1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | GENKYOTEX SUISSE SA (CH) | 2017-06-07 | — | — | EP | claimed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | claimed |
| EP-3980400-B1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | UNIV EMORY (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4319763-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-2776027-B1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | GENKYOTEX SUISSE SA (CH) | 2017-06-07 | — | — | EP | disclosed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | disclosed |
| EP-2776027-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | GENKYOTEX SA (CH) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068972-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013068972-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2013-05-16 | — | — | WO | disclosed |
| EP-2591782-A1 | Nadph oxidase 4 inhibitors and use thereof | Johann Wolfgang Goethe-Universität (DE) | 2013-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | MTAP, NSUN3, METTL3 | NOX4 2517/4885CYBB 4042/4885NOX5 3497/4885 |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | NOX1, NOX3, NOX4 | NOX4 3/4885CYBB 6/4885NOX5 4/4885 |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | PNP, MTAP, NOP2 | NOX4 3555/4885CYBB 4048/4885NOX5 2890/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | NOX4 3/4885CYBB 6/4885NOX5 4/4885 |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | NOX4 2891/4885CYBB 3145/4885NOX5 2253/4885 |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | NOX4, NOX1, NOX5 | NOX4 1/4885CYBB 6/4885NOX5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.